<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00042913</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069484</org_study_id>
    <secondary_id>UCLA-0201056</secondary_id>
    <secondary_id>AMGEN-AMG-412-159</secondary_id>
    <secondary_id>NCI-G02-2094</secondary_id>
    <nct_id>NCT00042913</nct_id>
  </id_info>
  <brief_title>Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase 2 Open Label, Randomized, Dose And Schedule Finding, Clinical Trial Of Immunotherapy With AMG 412 In Subjects With Diffuse Large B-Cell Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies such as epratuzumab can locate tumor cells and either kill&#xD;
      them or deliver tumor-killing substances to them without harming normal cells.&#xD;
&#xD;
      PURPOSE: Randomized phase II trial to study the effectiveness of epratuzumab in treating&#xD;
      patients who have non-Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the response rate of patients with diffuse large B-cell non-Hodgkin's lymphoma&#xD;
           treated with epratuzumab.&#xD;
&#xD;
        -  Determine the toxicity of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 3 treatment&#xD;
      arms.&#xD;
&#xD;
        -  Arm I: Patients receive low-dose epratuzumab IV over 1 hour once weekly for 4 weeks.&#xD;
&#xD;
        -  Arm II: Patients receive low-dose epratuzumab IV over 1 hour once weekly for 8 weeks.&#xD;
&#xD;
        -  Arm III: Patients receive high-dose epratuzumab IV over 1 hour once weekly for 4 weeks.&#xD;
&#xD;
      Patients are followed every 3 months for 2 years and then every 6 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 150 patients (50 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2002</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>epratuzumab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed diffuse large B-cell non-Hodgkin's lymphoma (NHL)&#xD;
&#xD;
               -  Relapsed or refractory after at least 1 regimen of standard therapy&#xD;
&#xD;
                    -  Prior therapy may include high-dose chemotherapy with autologous stem cell&#xD;
                       transplantation (ASCT) or immunotherapy&#xD;
&#xD;
          -  Bidimensionally measurable disease&#xD;
&#xD;
               -  At least 1 lesion at least 1.5 cm by CT scan&#xD;
&#xD;
          -  No primary or secondary CNS lymphoma&#xD;
&#xD;
          -  No HIV-related lymphoma&#xD;
&#xD;
          -  No known or suspected transformed lymphoma (prior or concurrent)&#xD;
&#xD;
          -  No bulky disease (i.e., any single mass greater than 10.0 cm)&#xD;
&#xD;
          -  No pleural effusion with positive cytology for lymphoma&#xD;
&#xD;
          -  Most recent pathology specimen available for collection&#xD;
&#xD;
          -  No rapid disease progression or symptoms that indicate disease progression requiring&#xD;
             rapid intervention within the past 2 weeks (e.g., severe shortness of breath, severe&#xD;
             pain, or gastrointestinal or genitourinary obstruction)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 4 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,000/mm3&#xD;
&#xD;
          -  Platelet count at least 50,000/mm3 (transfusion independent)&#xD;
&#xD;
          -  Hemoglobin at least 9.0 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT less than 5 times ULN&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
          -  Hepatitis C negative&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 2 times ULN&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No other primary malignancy within the past 3 years except squamous cell or basal cell&#xD;
             skin cancer, carcinoma in situ of the cervix, or stage I prostate cancer&#xD;
&#xD;
          -  No other serious nonmalignant condition that would preclude study&#xD;
&#xD;
          -  No serious infection&#xD;
&#xD;
          -  No known human antichimeric antibodies or human antihuman antibody positivity&#xD;
&#xD;
          -  No type 1 hypersensitivity or anaphylactic reactions to murine proteins&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for at least 6 months&#xD;
             after study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior immunotherapy (unless clearly progressing)&#xD;
&#xD;
          -  At least 12 weeks since prior ASCT&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (unless clearly progressing)&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radioimmunotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  At least 4 weeks since prior major surgery (unless patient has fully recovered)&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 30 days since prior enrollment in clinical trials involving investigational&#xD;
             devices or drugs&#xD;
&#xD;
          -  No concurrent enrollment in other clinical trials involving investigational devices or&#xD;
             drugs&#xD;
&#xD;
          -  No concurrent investigational agents for disease other than NHL&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christos E. Emmanouilides, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2003</verification_date>
  <study_first_submitted>August 5, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>December 18, 2013</last_update_submitted>
  <last_update_submitted_qc>December 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2013</last_update_posted>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epratuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

